Skip Nav Destination
Article navigation
Volume 30, Issue 17
1 September 2024
- Previous Article
- Next Article
CCR Perspectives in Regulatory Science and Policy| September 03 2024
Jorge E. Cortes
;
Jorge E. Cortes *
1
Georgia Cancer Center at Augusta University, Augusta, Georgia.
*Corresponding Author: Jorge E. Cortes, Georgia Cancer Center, 1410 Laney Walker Road, CN2222, Augusta, GA 30912. E-mail: jorge.cortes@augusta.edu
Search for other works by this author on:
This Site
Elisabetta Abruzzese
;
Elisabetta Abruzzese
2
Hematology, S. Eugenio Hospital, Tor Vergata University, Rome, Italy.
Search for other works by this author on:
This Site
Elyce H. Cardonick
;
Elyce H. Cardonick
3
Cooper Medical School of Rowan University, Camden, New Jersey.
Search for other works by this author on:
This Site
Sonia Hernández-Díaz
;
Sonia Hernández-Díaz
4
Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Search for other works by this author on:
This Site
Jamie Gutierrez
;
Jamie Gutierrez
5
Patient advocate, Castle Pines, Colorado.
Search for other works by this author on:
This Site
Mary S. Sardegna
;
Mary S. Sardegna
6
Patient advocate, Laguna Hills, California.
Search for other works by this author on:
This Site
Erica Torres-Chavez
;
Erica Torres-Chavez
7
Patient advocate, Riverside, California.
Search for other works by this author on:
This Site
Miriam Dinatale
;
Miriam Dinatale
8
FDA, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Silver Spring, Maryland.
Search for other works by this author on:
This Site
Catherine C. Lerro
;
Catherine C. Lerro
9
FDA, Oncology Center of Excellence, Silver Spring, Maryland.
Search for other works by this author on:
This Site
Brenda J. Gehrke
;
Brenda J. Gehrke
10
FDA, Center for Drug Evaluation and Research, Office of Oncologic Diseases, Silver Spring, Maryland.
Search for other works by this author on:
This Site
Stacy S. Shord
;
Stacy S. Shord
11
FDA, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Silver Spring, Maryland.
Search for other works by this author on:
This Site
R. Angelo De Claro
;
R. Angelo De Claro
10
FDA, Center for Drug Evaluation and Research, Office of Oncologic Diseases, Silver Spring, Maryland.
Search for other works by this author on:
This Site
Marc R. Theoret
;
Marc R. Theoret
9
FDA, Oncology Center of Excellence, Silver Spring, Maryland.
Search for other works by this author on:
This Site
Peter J. DeMaria
;
Peter J. DeMaria
8
FDA, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Silver Spring, Maryland.
Search for other works by this author on:
This Site
Kelly J. Norsworthy
Kelly J. Norsworthy
10
FDA, Center for Drug Evaluation and Research, Office of Oncologic Diseases, Silver Spring, Maryland.
Search for other works by this author on:
This Site
Author & Article Information
*Corresponding Author: Jorge E. Cortes, Georgia Cancer Center, 1410 Laney Walker Road, CN2222, Augusta, GA 30912. E-mail: jorge.cortes@augusta.edu
Clin Cancer Res 2024;30:3658–66
Received: March 19 2024
Revision Received: May 17 2024
Accepted: July 03 2024
Online ISSN: 1557-3265
Print ISSN: 1078-0432
Funding
Funding Group:
Award Group:
- Funder(s):
U.S. Food and Drug Administration (FDA)
- Principal Award Recipient(s): ,
C.C.
Lerro
,B.J.
Gehrke
,S.S.
Shord
,R.
Angelo de Claro
,M.R.
Theoret
,M.
Dinatale
,P.J.
DeMaria
K.J.
Norsworthy
- Funder(s):
©2024 American Association for Cancer Research
2024
American Association for Cancer Research
Clin Cancer Res (2024) 30 (17): 3658–3666.
Article history
Received:
March 19 2024
Revision Received:
May 17 2024
Accepted:
July 03 2024
- Views Icon Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
- Peer Review
- Tools Icon Tools
Cite Icon Cite
- Search Site
- Article Versions Icon Versions
- Version of Record September 3 2024
- Proof July 23 2024
- Accepted Manuscript July 5 2024
Citation
Jorge E. Cortes, Elisabetta Abruzzese, Elyce H. Cardonick, Sonia Hernández-Díaz, Jamie Gutierrez, Mary S. Sardegna, Erica Torres-Chavez, Miriam Dinatale, Catherine C. Lerro, Brenda J. Gehrke, Stacy S. Shord, R. Angelo De Claro, Marc R. Theoret, Peter J. DeMaria, Kelly J. Norsworthy; Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding. Clin Cancer Res 1 September 2024; 30 (17): 3658–3666. https://doi.org/10.1158/1078-0432.CCR-24-0826
Download citation file:
- Ris (Zotero)
- Reference Manager
- EasyBib
- Bookends
- Mendeley
- Papers
- EndNote
- RefWorks
- BibTex
Abstract
Tyrosine kinase inhibitors (TKI) have improved the outcome and life expectancy of patients with chronic myeloid leukemia (CML). Patients are diagnosed with CML at younger ages, and patients treated for CML may become pregnant or choose to breastfeed. The information available to date on the safety of TKIs during pregnancy and lactation and the optimal management of these patients is largely anecdotal, based on personal or small-group experience, and heterogeneous. A panel of interested parties was convened by U.S. Food and Drug Administration to analyze the current data and discuss possible solutions. Possible solutions include prospective data collection, in clinical trials and in routine clinical practice, a more uniform and specific data collection, and greater coordination among involved entities. As patients with cancer are living longer, frequently receiving therapies for extended periods of time (or for life), data on appropriate management of patients through different reproductive phases of life are needed. It is thus time to change our approach for how to study treatment of cancer (including CML) during pregnancy or breastfeeding to develop evidence-based guidelines for safe and effective patient care.
©2024 American Association for Cancer Research
2024
American Association for Cancer Research
You do not currently have access to this content.
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Reset password
Register
Pay-Per-View 24-Hour Access
$50.00
Purchase Article Access
0 Views
View Metrics
Citing articles via
Google Scholar
Advertisem*nt
Email alerts
Article Activity Alert
Online First Alert
eTOC Alert
Close Modal
- Latest
- Most Read
- Most Cited
Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
Genomic profiling and immune phenotyping of neuroendocrine bladder cancer
A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies